Glucagon-like peptide-1 receptor agonists as add-on therapy to basal insulin in patients with type 2 diabetes: a systematic review
Helen Berlie, Kathryn M Hurren, Nicole R PinelliEugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI, USAAbstract: The prevalence of obesity and diabetes continues to rise in the US. Glucagon-like peptide-1 receptor agonist (GLP-1RA) is an effective treatment...
Saved in:
Main Authors: | Berlie H, Hurren KM, Pinelli NR |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2012
|
Subjects: | |
Online Access: | https://doaj.org/article/fcaeb1feba014228bd09a1d02c9d7fcd |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A novel, long-acting glucagon-like peptide receptor-agonist: dulaglutide
by: Gurung T, et al.
Published: (2015) -
Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research
by: Levin PA, et al.
Published: (2017) -
Long-term management of type 2 diabetes with glucagon-like peptide-1 receptor agonists
by: Courtney H, et al.
Published: (2017) -
Insulin degludec as an ultralong-acting basal insulin once a day: a systematic review
by: Wang F, et al.
Published: (2012) -
Nephroprotective potential of glucagon-like peptide-1 receptor agonists
by: Minara S. Shamkhalova, et al.
Published: (2020)